Civica Partners With Phlow To Build $125m Injectables Facility In US
Operations Expected To Begin Within Three Years
Lauding a “dream come true,” Civica has announced plans to build its own injectables manufacturing facility via a strategic partnership with fellow public health firm Phlow Corporation.
You may also be interested in...
Fresh from its $812m government contract to help prevent shortages of essential medicines and shield the US market from global competition, domestic start-up Phlow Corporation has received further financial backing.
Sandoz and Civica Rx have entered into a long-term collaboration to help mitigate medicine shortages in US hospitals, where Sandoz will supply six critical injectables and Civica will ensure reliable supply of these medicines to patients.
US start-up Phlow has been awarded federal government funding of $354m as part of a contract to manufacture essential medicines in the US amid the COVID-19 pandemic, in partnership with AMPAC Fine Chemicals and Civica Rx.